Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A medulloblastoma SHH activated that is characterized as a molecular subtype by activation of the sonic hedgehog (SHH) pathway and the absence of TP53 mutations.
Biomarker and diagnostic research for medulloblastoma SHH activated and TP53 wild-type has been reported in the published literature.
No clinical trials have been registered for medulloblastoma SHH activated and TP53 wild-type.
5 publications have been identified in PubMed for medulloblastoma SHH activated and TP53 wild-type. Research spans Basic Science / Preclinical (40%), Diagnostic / Biomarker (20%), and Review / Meta-Analysis (20%).
Comer C (2026). [PMID: 41923098](https://pubmed.ncbi.nlm.nih.gov/41923098/). *Biol Direct*. [Basic Science / Preclinical]
Ruggiero A (2026). [PMID: 41899451](https://pubmed.ncbi.nlm.nih.gov/41899451/). *Curr Issues Mol Biol*. [Review / Meta-Analysis]
Ranade M (2025). [PMID: 40528003](https://pubmed.ncbi.nlm.nih.gov/40528003/). *Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery*. [Diagnostic / Biomarker]
Moreno DA (2025). [PMID: 40880425](https://pubmed.ncbi.nlm.nih.gov/40880425/). *Animal models and experimental medicine*. [Basic Science / Preclinical]
Cabezas-Camarero S (2024). [PMID: 38438322](https://pubmed.ncbi.nlm.nih.gov/38438322/). *The oncologist*. [Gene Therapy / Novel Therapeutics]
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 3:02 PM UTC